Edesa Biotech CEO awarded 1,671 RSUs

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity compensation award in the form of restricted share units.

Rhea-AI Filing Summary

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity compensation award in the form of restricted share units. He received 1,671 common shares at a price of $0.0000 per share, described as a grant or award acquisition.

The filing notes these restricted share units vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan. Following this award, Nijhawan directly holds 731,134 common shares, with additional indirect holdings reported through several related entities and a family trust, subject to customary beneficial ownership disclaimers.

Insider Trade Summary

Grant/Award: 1,671 shares

Grant/Award 5 txns

Insider Nijhawan Pardeep

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	1,671	$0.00	$0.00
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 731,134 shares (Direct); Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation); Common Shares — 32,609 shares (Indirect, Held by The New Nijhawan Family Trust 2015); Common Shares — 32,013 shares (Indirect, Held by The Digestive Health Clinic Inc.); Common Shares — 53,104 shares (Indirect, Held by 1968160Ontario Inc.)

Footnotes (3)

1. F1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
2. F2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3. F3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

RSU grant: 1,671 common shares Grant price: $0.0000 per share Direct holdings after grant: 731,134 common shares +4 more

7 metrics

RSU grant 1,671 common shares Restricted share unit award to CEO; Form 4 code A

Grant price $0.0000 per share Price per share for the 1,671-share award

Direct holdings after grant 731,134 common shares CEO Pardeep Nijhawan direct ownership following award

Indirect holding - 1968160 Ontario Inc. 53,104 common shares Total shares held by 1968160 Ontario Inc. after reporting date

Indirect holding - The Digestive Health Clinic Inc. 32,013 common shares Total shares held by The Digestive Health Clinic Inc.

Indirect holding - Family Trust 32,609 common shares Total shares held by The New Nijhawan Family Trust 2015

Indirect holding - Medicine Professional Corp. 402,702 common shares Total shares held by Pardeep Nijhawan Medicine Professional Corporation

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, beneficial ownership, pecuniary interest, +1 more

5 terms

restricted share units financial

"Reflects a grant of restricted share units, which vested in full upon grant"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

beneficial ownership regulatory

"shall not be deemed an admission of beneficial ownership of all of the reported shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest regulatory

"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"

co-trustee regulatory

"Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edesa Biotech (EDSA) report for CEO Pardeep Nijhawan?

Edesa Biotech reported that CEO Pardeep Nijhawan received an equity award of common shares. The Form 4 shows a grant of 1,671 restricted share units that vested immediately, increasing his directly held common shares to 731,134 after the award.

How many Edesa Biotech (EDSA) shares were granted to the CEO in this Form 4?

The Form 4 shows a grant of 1,671 common shares to CEO Pardeep Nijhawan. These shares were issued at a stated price of $0.0000 per share as a restricted share unit award under the company’s 2019 Equity Incentive Compensation Plan.

Did the Edesa Biotech (EDSA) CEO’s restricted share units vest immediately?

Yes. The filing explains the award reflects restricted share units that vested in full upon grant. This means the 1,671 common shares became fully vested right away under Edesa Biotech’s 2019 Equity Incentive Compensation Plan rather than vesting over time.

What are CEO Pardeep Nijhawan’s direct Edesa Biotech (EDSA) holdings after this grant?

After the grant, CEO Pardeep Nijhawan directly holds 731,134 common shares of Edesa Biotech. This total incorporates the 1,671-share restricted unit award reported in the Form 4 and represents his direct ownership position, separate from any indirect holdings.

What indirect Edesa Biotech (EDSA) holdings associated with the CEO are disclosed?

The Form 4 lists indirect holdings through entities including Pardeep Nijhawan Medicine Professional Corporation, 1968160 Ontario Inc., The Digestive Health Clinic Inc., and The New Nijhawan Family Trust 2015, with standard footnote language disclaiming beneficial ownership beyond his pecuniary interest.

What is the 2019 Equity Incentive Compensation Plan mentioned for Edesa Biotech (EDSA)?

The filing states the CEO’s award was granted under Edesa Biotech’s 2019 Equity Incentive Compensation Plan. This plan is used to issue equity-based compensation, such as restricted share units, to executives and other participants as part of their overall compensation structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/01/2026		A		1,671(1)	A	$0(1)	731,134	D
Common Shares								402,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(2)
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(3)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160Ontario Inc.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)